Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E, Andreis D, Fabbri F, Menna C, Schirone A, Kopf B, Rocca A, Amadori D, De Giorgi U. Pietri E, et al. Among authors: kopf b. Oncologist. 2015 Mar;20(3):239-40. doi: 10.1634/theoncologist.2014-0326. Epub 2015 Jan 30. Oncologist. 2015. PMID: 25637379 Free PMC article. Clinical Trial.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators. Pignata S, et al. Among authors: kopf b. Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9. Gynecol Oncol. 2019. PMID: 30979589 Free article. Clinical Trial.
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
De Giorgi U, Giannini M, Frassineti L, Kopf B, Palazzi S, Giovannini N, Zumaglini F, Rosti G, Emiliani E, Marangolo M. De Giorgi U, et al. Among authors: kopf b. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1165-9. doi: 10.1016/j.ijrobp.2006.02.018. Epub 2006 May 6. Int J Radiat Oncol Biol Phys. 2006. PMID: 16682141 Clinical Trial.
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
De Giorgi U, Rosti G, Ciucci G, Kopf B, Minzi C, Argnani M, Marangolo M. De Giorgi U, et al. Among authors: kopf b. Bone Marrow Transplant. 2007 Oct;40(8):735-9. doi: 10.1038/sj.bmt.1705793. Epub 2007 Aug 13. Bone Marrow Transplant. 2007. PMID: 17700603
High-dose chemotherapy for triple negative breast cancer.
De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F, Marangolo M. De Giorgi U, et al. Among authors: kopf b. Ann Oncol. 2007 Jan;18(1):202-203. doi: 10.1093/annonc/mdl306. Epub 2006 Sep 13. Ann Oncol. 2007. PMID: 16971660 Free article. Clinical Trial. No abstract available.
142 results